Inhaled beclometasone dipropionate/formoterol extra-fine fixed combination in the treatment of asthma: evidence and future perspectives

被引：41

作者：

Fabbri, Leonardo Michele ^{[1
]}

Nicolini, Gabriele ^{[2
]}

Olivieri, Dario ^{[3
,4
]}

Papi, Alberto ^{[5
]}

机构：

[1] Univ Modena & Reggio Emilia, Dept Resp Dis, I-41100 Modena, Italy

[2] Chiesi Farmaceut, Dept Med, Parma, Italy

[3] Univ Parma, Cardiopulm Dept, Sect Resp Dis, I-43100 Parma, Italy

[4] Univ Ferrara, Res Ctr Asthma, I-44100 Ferrara, Italy

[5] COPD, Ferrara, Italy

来源：

EXPERT OPINION ON PHARMACOTHERAPY | 2008年 / 9卷 / 03期

关键词：

asthma; beclometasone dipropionate/formoterol; combination therapy; extra-fine; HFA; Modulite (R); BECLOMETHASONE DIPROPIONATE; SINGLE INHALER; SYMBICORT(R) TURBUHALER(R); SMALL AIRWAYS; MU-G; FORMOTEROL; BUDESONIDE; EFFICACY; MODERATE; BUDESONIDE/FORMOTEROL;

D O I：

10.1517/14656566.9.3.479

中图分类号：

R9 [药学];

学科分类号：

100702 [药剂学];

摘要：

Background: Combinations of a long-acting beta(2)-agonist (LABA) and an inhaled corticosteroid (ICS) are effective and safe options in asthma management. Objective: To review available data on a recently developed combination of beclometasone dipropionate (BDP) and formoterol (F) given via a pressurized metered-dose inhaler. Methods: Published data on preclinical and clinical studies were reviewed. Results/conclusion: In the treatment of asthma, BDP/F was shown to be at least as effective and well-tolerated as other available combinations of ICS and LABA with the advantage of a better cost effectiveness, and more effective in improving asthma control than BDP and formoterol given via separate inhalers. The extra-fine BDP/F combination appears to be a valuable therapeutic option in the management of asthma.

引用

页码：479 / 490

页数：12

共 43 条

[1]

Advances in asthma and COPD management:: Delivering CFC-free inhaled therapy using Modulite® technology [J].

Acerbi, D. ;

Brambilla, G. ;

Kottakis, I. .

PULMONARY PHARMACOLOGY & THERAPEUTICS, 2007, 20 (03) :290-303

[2]

Salmeterol/fluticasone propionate (50/500 μg) in combination in a Diskus® inhaler (Seretide®) is effective and safe in the treatment of steroid-dependent asthma [J].

Aubier, M ;

Pieters, WR ;

Schlösser, NJJ ;

Steinmetz, KO .

RESPIRATORY MEDICINE, 1999, 93 (12) :876-884

[3]

Scientific rationale for inhaled combination therapy with long-acting β2-agonists and corticosteroids [J].

Barnes, PJ .

EUROPEAN RESPIRATORY JOURNAL, 2002, 19 (01) :182-191

[4]

Bateman Eric D, 2003, Am J Respir Med, V2, P275

[5]

BONNETGONOD F, 2006, EUR RESP J S50, V28, pP1230

[6]

BECLOMETHASONE DIPROPIONATE - A REAPPRAISAL OF ITS PHARMACODYNAMIC PROPERTIES AND THERAPEUTIC EFFICACY AFTER A DECADE OF USE IN ASTHMA AND RHINITIS [J].

BROGDEN, RN ;

HEEL, RC ;

SPEIGHT, TM ;

AVERY, GS .

DRUGS, 1984, 28 (02) :99-126

[7]

Chapman K R, 1999, Can Respir J, V6, P45

[8]

CREMONESI G, 2007, 8 NAT UIP C 4 7 DEC

[9]

Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man [J].

Daley-Yates, PT ;

Price, AC ;

Sisson, JR ;

Pereira, A ;

Dallow, N .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 51 (05) :400-409

[10]

Dhillon S, 2006, DRUGS, V66, P1475, DOI 10.2165/00003495-200666110-00005

← 1 2 3 4 5 →